The FDA approved a supplemental application for Wegovy (semaglutide) on March 19, 2026. This approval, designated as an efficacy supplement, was submitted by the sponsor, Novo Nordisk.
Background
Wegovy is the brand name for semaglutide, an active ingredient. This latest regulatory action by the FDA involves a supplemental application focused on the efficacy of the drug, identified as NDA 215256 S-29.
What this means
A supplemental efficacy approval for Wegovy (semaglutide) indicates that the FDA has reviewed additional data supporting the drug's effectiveness. While the specific details of the data reviewed are not provided in this update, such approvals typically expand or refine the understanding of a drug's therapeutic profile, potentially impacting its use in clinical practice or providing further evidence for its established indications.
Source
The information regarding this FDA approval was obtained from the official FDA website, accessdata.fda.fda.gov. The approval for supplemental application NDA 215256 S-29 for Wegovy (semaglutide) was posted on March 19, 2026.